Clinical Vignette
Patient: "Ms. J," 33-year-old marketing manager, self-referred after tracking her mood and realizing that her 'worst days' consistently occur in the week before her menstrual period.
Chief Concern: "For 7-10 days before my period, I become a completely different person. I'm irritable, anxious, tearful, and I can't function at work. My partner says I'm impossible to be around. Then my period starts and within 2 days I'm completely fine. This has been happening for years."
History of Present Illness: Ms. J reports a consistent pattern of severe premenstrual symptoms over the past 5 years. During the luteal phase (7-10 days before menses), she experiences marked mood lability with sudden tearfulness, intense irritability with outbursts at coworkers and partner, anxiety and tension, anhedonia, difficulty concentrating, fatigue, sleep disruption, breast tenderness, and bloating. She describes 2-3 interpersonal conflicts per cycle that occur exclusively during this phase. Her irritability has led to two formal complaints at work. Within 1-2 days of menstrual onset, all symptoms resolve completely, and she functions at her baseline: productive, sociable, even-tempered. During the follicular phase (days 5-14), she has zero mood symptoms. She brought 3 months of prospective daily mood ratings showing a consistent pattern: symptom scores of 1-2 (out of 10) during follicular phase, rising to 7-9 during the final 7-10 days of the luteal phase, dropping to 1-2 within 48 hours of menses onset.
Medical History: Regular 28-day menstrual cycles. No hormonal contraception. No endocrine disorders. No other medical conditions.
Mental Status Exam: Currently in follicular phase (day 8). Alert, cooperative, pleasant. Speech normal. Mood 'good.' Affect bright, engaged. No anxiety, irritability, or tearfulness. No psychotic symptoms. Insight excellent. She brought printed mood charts.
Step 1: PMDD DSM-5-TR Criteria
DSM-5-TR requires that in the majority of menstrual cycles, at least 5 symptoms are present in the final week before menses, improve within a few days after onset, and become minimal/absent in the week postmenses. At least one must be from B1-B4:
B1: Marked affective lability
Sudden tearfulness, rapid mood shifts during luteal phase. PRESENT.
B2: Marked irritability or anger or increased interpersonal conflicts
Intense irritability with outbursts. 2-3 interpersonal conflicts per cycle exclusively during luteal phase. Two formal work complaints. PRESENT.
B3: Markedly depressed mood, feelings of hopelessness, self-deprecating thoughts
Describes herself as 'impossible to be around' during luteal phase. Anhedonia present. PRESENT.
B4: Marked anxiety, tension, feeling keyed up or on edge
Reports significant anxiety and tension during premenstrual phase. PRESENT.
B5: Decreased interest in usual activities
Anhedonia during luteal phase: declines social plans, disengages from hobbies. PRESENT.
B6: Subjective difficulty in concentration
Reports difficulty focusing at work during premenstrual days. PRESENT.
B7: Lethargy, easy fatigability, marked lack of energy
Fatigue described during luteal phase. PRESENT.
B8: Marked change in appetite
Increased appetite with carbohydrate cravings during luteal phase. PRESENT.
B9: Hypersomnia or insomnia
Sleep disruption reported during premenstrual week. PRESENT.
B11: Physical symptoms (breast tenderness, bloating)
Breast tenderness and bloating during luteal phase. PRESENT.
Total: 10 symptoms (4/4 from B1-B4, 6 additional). ≥5 required with ≥1 from B1-B4.
Far exceeds threshold. CRITERIA MET.
Criterion C: Clinically significant distress or interference
Two formal work complaints. Interpersonal conflicts with partner. Avoidance of social engagements. MET.
Criterion D: Prospective daily rating confirmation for ≥2 symptomatic cycles
Three months of prospective daily mood charts provided, showing consistent luteal phase symptom elevation and follicular phase resolution. MET — PROSPECTIVE CONFIRMATION.
Step 2: Differentiating PMDD from PMS and Premenstrual Exacerbation of MDD
| Feature | PMS | PMDD | Premenstrual Exacerbation of MDD | This Patient |
|---|---|---|---|---|
| Severity | Mild, manageable | Severe, impairing | MDD worsens premenstrually | PMDD: severe impairment at work and relationships |
| Mood symptoms | Mild moodiness | Marked lability, irritability, depression | MDD symptoms present throughout cycle | PMDD: 4/4 core mood criteria met |
| Follicular phase | Asymptomatic | Completely asymptomatic | Symptomatic (MDD persists, milder) | Completely asymptomatic (scores 1-2/10) |
| Functional impairment | Minimal | Significant | Impaired throughout cycle | Significant but ONLY during luteal phase |
| Prospective charting | Confirms mild symptoms | Confirms severe luteal pattern | Shows baseline + premenstrual worsening | Confirms pure luteal pattern |
Differential Summary
The complete resolution of symptoms during the follicular phase (prospectively confirmed) rules out MDD with premenstrual exacerbation (which would show persistent symptoms with premenstrual worsening). The severity and functional impairment exceed PMS. PMDD is confirmed.
Diagnostic Formulation
Diagnostic Conclusion
Premenstrual Dysphoric Disorder (N94.3): All DSM-5-TR criteria met. Ten symptoms present during luteal phase with complete follicular resolution. Prospective daily rating for 3 cycles confirms the pattern. Significant functional impairment (occupational and interpersonal). Treatment: first-line is SSRI (continuous or luteal-phase dosing), with hormonal options as second-line.
Teaching Points
- DSM-5-TR requires prospective daily symptom ratings for at least 2 symptomatic cycles to confirm PMDD. Retrospective reporting alone is insufficient for the diagnosis because recall bias leads to overestimation of premenstrual symptoms.
- The critical differentiator between PMDD and premenstrual exacerbation of an existing disorder (MDD, GAD, BPD) is the follicular phase: PMDD requires COMPLETE symptom resolution during the follicular phase. Any persistent symptoms during the follicular phase suggest an underlying disorder with premenstrual worsening.
- PMDD is a depressive disorder in DSM-5-TR (classified under Depressive Disorders), reflecting its mood-dominant presentation despite the menstrual cycle trigger. This classification acknowledges the neurobiological basis rather than framing it as a reproductive health condition alone.
- SSRIs are effective for PMDD and can be used either continuously or during the luteal phase only. Luteal-phase-only dosing (starting at anticipated ovulation, stopping at menses onset) is effective and reduces total medication exposure. The rapid SSRI response in PMDD (within days) contrasts with the 2-4 week delay in MDD, suggesting a different mechanism of action.
- Oral contraceptives (particularly those containing drospirenone) and GnRH agonists are second-line treatments for PMDD. These options are considered when SSRIs are ineffective, not tolerated, or when the patient prefers hormonal management.